Recombinetics, Inc.
Saint Paul, MN · CIK 0001543926 · Biotech · Acquired
Custom gene-edited swine models for biomedical research and agricultural applications
recombinetics.com →- Grants
- $9.8M
- 19 awards
- Sector median: 1
- Raised
- $45M
- 8 Form D · Sep 2018
- 97 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 5 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $330,000 | |
| Private capital raised | Form D · SEC | $35,000 | |
| Private capital raised | Form D · SEC | $540,800 | |
| Federal grant | Department of Health and Human Services · Phase I · Multiplex gene-editing to create multi-lineage ablated hosts for exogenic organ production | $301,098 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and maintenance of T, B and NK-cell deficient swine by multiplex gene-editing and immune restoration | $376,083 | |
| Private capital raised | Form D · SEC | $2,770,250 | |
| Federal grant | Department of Health and Human Services · Phase I · Generating a Porcine Model for Human Microvillus Inclusion Disease (MVID) by Gene Editing | $394,730 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and Characterization of a Swine Model of Phenylketonuria | $355,198 | |
| Private capital raised | Form D · SEC | $630,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A Humanized Swine Model for Alzheimer's Disease | $358,338 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development and Characterization of a Swine Model of Neurofibromatosis Type 2 | $347,891 | |
| Private capital raised | Form D · SEC | $6,982,500 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of a genetic swine model of non alcoholic steatohepatitis NASH by gene editing | $398,884 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of a genetic swine model of non-alcoholic steatohepatitis (NASH) by gene-editing | $398,884 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of swine model of COPD by integrating genetic and environmental risk factors | $398,696 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a porcine model of polycystic kidney disease by multiplex gene-editing. | $749,640 | |
| Private capital raised | Form D · SEC | $82,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Modeling Disease in Swine by Transplantation of Gene Targeted Germ Cells | $1,997,106 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a porcine model of polycystic kidney disease by multiplex gene-editing. | $728,169 | |
| Private capital raised | Form D · SEC | $33,510,969 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and Evaluation of a Thrombospondin 2 Deficient Pig as an Improved Source of Biomaterial | $398,952 | |
| Federal grant | Department of Health and Human Services · Phase I · A Swine Model of Glioblastoma | $299,188 | |
| Federal grant | Department of Health and Human Services · Phase I · Swine model of monogenic diabetes with potential implications for T1D, T2D, and double diabetes | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Modeling Disease in Swine by Transplantation of Gene Targeted Germ Cells | $1,010,357 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and Characterization of a Preclinical Swine Model of Osteogenesis Imperfecta | $224,773 | |
| Federal grant | Department of Health and Human Services · Phase I · An Inducible Swine Hepatocellular Carcinoma Platform for Enhanced Therapeutic Development | $342,154 | |
| Federal grant | Department of Health and Human Services · Phase I · Gene Therapy for MPS IV A in a Novel Porcine Model of the Disease | $384,999 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1852 | VERSAPEUTICS INC | — | $3.8M |
| 1853 | TBC I LLC | — | $1.0M |
| 1854 | InCarda Therapeutics, Inc. | — | $66M |
| 1855 | Recombinetics, Inc. | — | $45M |
| 1856 | Dracen Pharmaceuticals, Inc. | — | $19M |
| 1857 | Ibex Investment Holdings II LLC | — | $1.0M |
| 1858 | Purinomia Biotech, Inc. | — | $10M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David AberleExecutive Officer
- Mitch AbrahamsenDirector
- Mitchell Abrahamsen, Ph.D.Director · Executive Officer
- Mitchell Abramhamsen, Ph.D.Director · Executive Officer
- Jerry ArndtDirector
- John BurtisExecutive Officer
- John CameronExecutive Officer
- Daniel Carlson, Ph.D.Executive Officer
- Kyle DawleyExecutive Officer
- Scott FahrenkrugDirector · Executive Officer
- SCOTT FAHRENKRUGDirector · Executive Officer
- Scott Fahrenkrug, Ph.D.Director · Executive Officer · Promoter
- Bill FarrellDirector
- Ian FriendlyDirector · Executive Officer
- Perry Hacket, Ph.D.Director
- Perry Hackett, Ph.D.Director · Executive Officer
- Peter HajasDirector
- Cliff HoffmanDirector
- Douglas KeethDirector
- Jim KilmanDirector
- Wendell KingDirector
- Mark Kroll, Ph.D.Director
- Tammy LeeExecutive Officer
- William McKnight, Jr.Director
- Greg MelsenDirector
- Paul OlsonDirector
- Paul Olson, Ed.D.Director
- Scott RathgaberDirector
- Tad Sonstegard, Ph.D.Executive Officer
- Tammy StanochExecutive Officer
- Tammy StanockExecutive Officer
- Robert SwitzDirector
- Mark Walton, Ph.D.Executive Officer
- Justin ZenankoDirector · Executive Officer
Patents
- Media And Methods For Making And Maintaining Porcine Pluripotent Stem Cellsapplication
- Non-meiotic Allele Introgressionapplication
- Methods For Making Genetic Editsapplication
- Methods For Making Genetic Editsgranted
- Efficient Non-meiotic Allele Introgression In Livestockapplication
- Efficient Non-meiotic Allele Introgression In Livestockgranted
- Production Method For Animal Models With Disease Associated Phenotypesapplication
- Non-meiotic Allele Introgressionapplication
- Non-meiotic Allele Introgressiongranted
- Non-meiotic Allele Introgressiongranted
- Inducible Disease Models Methods Of Making Them And Use In Tissue Complementationapplication
- Non-meiotic Allele Introgressiongranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.